A Safety, Tolerability, PD and PK Study in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Healthy

Interventions

DRUG

Open-label TRV734 125 mg

125 mg

DRUG

TRV734 blinded

blinded, multiple ascending dose

DRUG

Oxycodone IR 10 mg

DRUG

Placebo

TRV734-matched and oxycodone placebo

Trial Locations (1)

ICON Development Solutions, San Antonio

All Listed Sponsors

lead

Trevena Inc.

INDUSTRY

NCT02211625 - A Safety, Tolerability, PD and PK Study in Healthy Adults | Biotech Hunter | Biotech Hunter